Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation

Radiation Oncology Investigations

Volumn 7, Issue 3, 1999, Pages 163-169

  El Said, Amr ^a   Menke, Douglas ^a   Dorie, Mary Jo ^a   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbogen; Fractionated radiation; Hypoxia; Nicotinamide; Tirapazamine

Indexed keywords

CARBOGEN; NICTINDOLE; TIRAPAZAMINE;

ANIMAL TISSUE; ARTICLE; CELL HYPOXIA; CELL SURVIVAL; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INHALATIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; CARBON DIOXIDE; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NIACINAMIDE; OXYGEN; OXYGEN CONSUMPTION; PHARYNGEAL NEOPLASMS; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; SENSITIVITY AND SPECIFICITY; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0033061292     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:3<163::AID-ROI5>3.0.CO;2-M     Document Type: Article

References (41)

1. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-838.
2. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-40.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
4. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994; 6:509-518.
5. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-156.
6. Brown JM. Hypoxic cell radiosensitizers: the end of an era? Regarding Lee et al., IJROBP 1995;32:567-576 [editorial]. Int J Radiat Oncol Biol Phys 1995;32:883-885.
7. Horsman MR, Chaplin DJ, Brown JM. Tumor radiosensitization by nicotinamide: a result of improved blood perfusion and oxygenation. Radiat Res 1989;118: 139-150.
8. Horsman MR, Nordsmark M, Khalil AA, Hill SA, Chaplin DJ, Siemann DW, Overgaard J. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol 1994;33:371-376.
9. Honess DJ, Bleehen NM. Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer 1995;71:1175-1180.
10. Robinson SP, Howe FA, Griffiths JR. Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging [see comments]. Int J Radiat Oncol Biol Phys 1995;33:855-859.
11. Rojas A, Hirst VK, Calvert AS, Johns H. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys 1996;34:357-365.
12. Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 1995;34: 571-587.
13. Laurence VM, Ward R, Dennis IF, Bleehen NM. Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. BrJ Cancer 1995;72: 198-205.
14. Stuben G, Stuschke M, Knuhmann K, Horsman MR, Sack H. The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. Radiother Oncol 1998;48:143-148.
15. Kaanders JH, Pop LA, Marres HA, Liefers J, van den Hoogen FJ, van Daal WA, van der Kogel AJ. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998; 48:115-122.
16. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12:1239-1242.
17. Kim IH, Brown JM. Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 1994;29:493-497.
18. Durand RE, Olive PL. Physiological and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Invest 1997;5:213-219.
19. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53:4633-4636.
20. von Pawel J, von Roemeling R. Survival benefit from tirazone (tirapazamine) and cisplatin in advanced nonsmall cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT 1 trial. Proc Am Soc Clin Oncol 1998;17:454a Abstr #1749.
21. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990;50: 7745-7749.
22. Brown JM, Lemmon MJ. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother Oncol 1991;20:151-156.
23. Brown JM, Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 1991;20:457-461.
24. Lee D-J, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, Harvey E, Groves E. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 1998;42:811-815.
25. Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst 1991;83:178-185.
26. Dorie MJ, Menke D, Brown JM. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys 1994;28: 145-150.
27. Sum BG, van Zijl PL, Brown JM. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 1996;73:952-960.
28. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, Mariscal C, Rampling R, Senan S, Roemeling RV. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 1994;29:379-382.
29. Rojas A. Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol 1991;20(Suppl. I): 65-70.
30. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 1980;64:595-604.
31. Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993;67:1163-1170.
32. Siim BG, Menke DR, Done MJ, Brown JM. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 1997;57:2922-2928.
33. Chaplin DJ, Horsman MR, Aoki D. Nicotinamide, fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer 1991;63:109-113.
34. Kjellen E, Joiner MC, Collier JM, Johns H, Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol 1991;22:81-91.
35. Kaanders JH, Stratford MR, Liefers J, Dennis MF, van der Kogel AJ, van Daal WA, Rojas A. Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. Radiother Oncol 1997;43:67-73.
36. Horsman MR, Chaplin DJ, Brown JM. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res 1987;109:479-489.
37. Horsman MR, Siemann DW, Chaplin DJ, Overgaard J. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol 1997;45:167-174.
38. Brown JM. Carbogen and nicotinamide: expectations too high? Radiother Oncol 1992;24:75-76.
39. Walton MI, Workman P. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. J Pharmacol Exp Ther 1993;265:938-947.
40. Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose escalation strategy in a phase I trial. Cancer Chemother Pharmacokinet 1997;40:1-10.
41. Rojas AM, Johns H, Fiat PR. Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimens? Int J Radiat Oncol Biol Phys 1993;27:1101-1105.